Steve Kelsey

Steve Kelsey

Company: Revolution Medicines

Job title: President R&D


Approaches to Inhibiting RAS Driven Tumors Beyond KRAS G12C 9:00 am

Targeting the ON form of KRAS G12C Targeting mutant form of RAS beyond G12C Relevant combinations to achieve synergy in KRAS mutant cancersRead more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.